TISIDB

Summary
Symbol	MBD2
Name	methyl-CpG binding domain protein 2
Aliases	DMTase; NY-CO-41; demethylase; Methyl-CpG-binding protein MBD2; Methyl-CpG-binding domain protein 2
Chromosomal Location	18q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus Note=Nuclear, in discrete foci. Detected at replication foci in late S phase.
Domain	PF01429 Methyl-CpG binding domain PF14048 C-terminal domain of methyl-CpG binding protein 2 and 3 PF16564 p55-binding region of Methyl-CpG-binding domain proteins MBD
Function	Binds CpG islands in promoters where the DNA is methylated at position 5 of cytosine within CpG dinucleotides. Binds hemimethylated DNA as well. Recruits histone deacetylases and DNA methyltransferases. Acts as transcriptional repressor and plays a role in gene silencing. Functions as a scaffold protein, targeting GATAD2A and GATAD2B to chromatin to promote repression. May enhance the activation of some unmethylated cAMP-responsive promoters.

> Gene Ontology [ TOP ]
Biological Process	GO:0000183 chromatin silencing at rDNA GO:0006304 DNA modification GO:0006305 DNA alkylation GO:0006306 DNA methylation GO:0006338 chromatin remodeling GO:0006342 chromatin silencing GO:0006346 methylation-dependent chromatin silencing GO:0007507 heart development GO:0007568 aging GO:0009612 response to mechanical stimulus GO:0009991 response to extracellular stimulus GO:0016055 Wnt signaling pathway GO:0016458 gene silencing GO:0019098 reproductive behavior GO:0030111 regulation of Wnt signaling pathway GO:0030177 positive regulation of Wnt signaling pathway GO:0031667 response to nutrient levels GO:0032259 methylation GO:0032355 response to estradiol GO:0035561 regulation of chromatin binding GO:0035563 positive regulation of chromatin binding GO:0040029 regulation of gene expression, epigenetic GO:0042711 maternal behavior GO:0043044 ATP-dependent chromatin remodeling GO:0043414 macromolecule methylation GO:0044030 regulation of DNA methylation GO:0044728 DNA methylation or demethylation GO:0045814 negative regulation of gene expression, epigenetic GO:0048568 embryonic organ development GO:0051052 regulation of DNA metabolic process GO:0051098 regulation of binding GO:0051099 positive regulation of binding GO:0060746 parental behavior GO:0071407 cellular response to organic cyclic compound GO:0198738 cell-cell signaling by wnt
Molecular Function	GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000980 RNA polymerase II distal enhancer sequence-specific DNA binding GO:0000987 core promoter proximal region sequence-specific DNA binding GO:0001158 enhancer sequence-specific DNA binding GO:0001159 core promoter proximal region DNA binding GO:0003682 chromatin binding GO:0003696 satellite DNA binding GO:0003729 mRNA binding GO:0008327 methyl-CpG binding GO:0031490 chromatin DNA binding GO:0031491 nucleosome binding GO:0031492 nucleosomal DNA binding GO:0035197 siRNA binding GO:0035326 enhancer binding GO:0043566 structure-specific DNA binding GO:0070742 C2H2 zinc finger domain binding
Cellular Component	GO:0000118 histone deacetylase complex GO:0000785 chromatin GO:0000790 nuclear chromatin GO:0000792 heterochromatin GO:0044454 nuclear chromosome part

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-212165: Epigenetic regulation of gene expression R-HSA-74160: Gene Expression R-HSA-5250941: Negative epigenetic regulation of rRNA expression R-HSA-427413: NoRC negatively regulates rRNA expression R-HSA-73854: RNA Polymerase I Promoter Clearance R-HSA-73728: RNA Polymerase I Promoter Opening R-HSA-73864: RNA Polymerase I Transcription R-HSA-504046: RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription

> KEGG and Reactome Pathway

[ TOP ]

KEGG

Reactome

R-HSA-212165: Epigenetic regulation of gene expression
R-HSA-74160: Gene Expression
R-HSA-5250941: Negative epigenetic regulation of rRNA expression
R-HSA-427413: NoRC negatively regulates rRNA expression
R-HSA-73854: RNA Polymerase I Promoter Clearance
R-HSA-73728: RNA Polymerase I Promoter Opening
R-HSA-73864: RNA Polymerase I Transcription
R-HSA-504046: RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription

Summary
Symbol	MBD2
Name	methyl-CpG binding domain protein 2
Aliases	DMTase; NY-CO-41; demethylase; Methyl-CpG-binding protein MBD2; Methyl-CpG-binding domain protein 2
Chromosomal Location	18q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between MBD2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between MBD2 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
29603746	Colon Carcinoma	Promote immunity	As environmental interactions within the intestine can alter DNA methylation patterns, we propose that Mbd2 plays a key role in determining whether these interactions are anti- or pro-tumourigenic and this makes it a useful new epigenetic model for inflammation-associated carcinogenesis.

Summary
Symbol	MBD2
Name	methyl-CpG binding domain protein 2
Aliases	DMTase; NY-CO-41; demethylase; Methyl-CpG-binding protein MBD2; Methyl-CpG-binding domain protein 2
Chromosomal Location	18q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of MBD2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	MBD2
Name	methyl-CpG binding domain protein 2
Aliases	DMTase; NY-CO-41; demethylase; Methyl-CpG-binding protein MBD2; Methyl-CpG-binding domain protein 2
Chromosomal Location	18q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of MBD2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.106	0.636
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.196	0.916
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.043	0.974
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.037	0.89
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.103	0.957
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.216	0.93
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.106	0.786
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.194	0.908
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.019	0.992
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.313	0.838
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.382	0.873
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.008	0.919

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of MBD2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	6.2	4.9	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	MBD2
Name	methyl-CpG binding domain protein 2
Aliases	DMTase; NY-CO-41; demethylase; Methyl-CpG-binding protein MBD2; Methyl-CpG-binding domain protein 2
Chromosomal Location	18q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MBD2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	MBD2
Name	methyl-CpG binding domain protein 2
Aliases	DMTase; NY-CO-41; demethylase; Methyl-CpG-binding protein MBD2; Methyl-CpG-binding domain protein 2
Chromosomal Location	18q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MBD2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MBD2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	MBD2
Name	methyl-CpG binding domain protein 2
Aliases	DMTase; NY-CO-41; demethylase; Methyl-CpG-binding protein MBD2; Methyl-CpG-binding domain protein 2
Chromosomal Location	18q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MBD2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	MBD2
Name	methyl-CpG binding domain protein 2
Aliases	DMTase; NY-CO-41; demethylase; Methyl-CpG-binding protein MBD2; Methyl-CpG-binding domain protein 2
Chromosomal Location	18q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of MBD2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	MBD2
Name	methyl-CpG binding domain protein 2
Aliases	DMTase; NY-CO-41; demethylase; Methyl-CpG-binding protein MBD2; Methyl-CpG-binding domain protein 2
Chromosomal Location	18q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between MBD2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	MBD2
Name	methyl-CpG binding domain protein 2
Aliases	DMTase; NY-CO-41; demethylase; Methyl-CpG-binding protein MBD2; Methyl-CpG-binding domain protein 2
Chromosomal Location	18q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting MBD2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse MBD2